From contact lenses to cancer treatments, Johnson & Johnson has a robust portfolio of healthcare products—and Rich Kaeser is tasked with ensuring the safety and quality of all of the company’s brands.

Hundreds of millions of people worldwide have type 2 diabetes. And Chiara Magnone has her sights set on changing what it means to live with the condition, as well as how common complications like chronic kidney disease are treated.

Trillions of beneficial bacteria live in and all around us. What if we could use them to our advantage, to do everything from prevent diabetes to reduce inflammation? Dirk Gevers, Ph.D., Global Head of the Janssen Human Microbiome Institute, shares how his team is already well on that research path.

Johnson & Johnson aspires to change the trajectory of health for humanity. And Tom Heyman helps make that lofty goal a reality through his work as the head of Johnson & Johnson’s venture capital division, which invests in dozens of companies each year. He shares what’s on his radar for 2019.